Research Store

Research Store

Research Store
add to cart Register yourself and then log-in with your user ID and password, before clicking on 'Add to Cart'
Issue Date:09 June 2017     Price in Rs. R 6500    Price in USD. $ 100

Serum Institute of India Pvt. Ltd. is among the few Indian pharma companies who are global leader in their own domain. Serum is undisputably the largest vaccine manufacturer by number of doses produced and sold globally. It has crossed 1.3 billion doses mark recently.

It's vaccines portfolio includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. It is the world's largest producer of measles and Diphtheria, Tetanus and Pertussis (DTP) group of vaccines. Two out of every three children immunised in the world is vaccinated by a vaccine manufactured by Serum Institute. It's products are exported and used in 140 countries across the globe.

Founded in 1966, Serum Institute, started wuth the aim of manufacturing life-saving immuno-biologicals, which were in shortage in the country and imported at high prices, at that time. Subsequently, many life-saving biologicals were manufactured at very affordable prices to the common man and in large volume, so as the country became self-sufficient for tetanus anti-toxin and anti-snake venom serum, followed by DTP group of vaccines and then later on measles, mumps and rubella (MMR) group of vaccines.

Serum Institute recently set up the Serum Bio Pharma Park, India's first biotech special economic zone (SEZ). The Park is adjoining Serum Institute's existing manufacturing unit and is a sector-specific SEZ meant for biotechnology and pharmaceutical products.

Besides biologicals (vaccines), Serum also manufactures many pharma products for the Indian market. In fact, an anti-rehumatics (NSAIDS) which is Nimesulide combination based product, under the brand name SN-15, is one of its largest selling pharma product. It also has a portfolio of hormonal contraceptives (Progesterone and Medroxyprogesterone based), under the brand names - Strone and Meprate, which also do well in the market.

Other than common vaccines, Serum is also one of the leading player in combination vaccines, under the brand name Pentavac, combination of DTP, HepB and Hib.

Financially company has done quite well and has enjoyed a high CAGR of more than 30%. In the FY2016, it clocked the total revenue of around Rs. 4374 crore with operating profit of over Rs. 2530 crore. Other income was Rs. 278 crore. With Interest and Depreciation at Rs. 9 crore and Rs. 172 crore respectively, PBT was Rs. 2628 crore. PAT was over Rs. 2413 crore. Total debt stood at just about Rs. 99 crore.

  1. Company Background
  2. Business Highlights
  3. Financial Performance
  4. Financial Details


  1. Board of Directors
  2. Financial Summary
  3. Profit & Loss Account
  4. Balance Sheet
  5. Ratios


Serum Institute of India Pvt. Ltd.